At a glance
The selected evidence connects preclinical albumin-binding pharmacology with short controlled human hormone-response trials. It is strongest for the measured endocrine response, rather than a performance outcome.
Identity & scope
The long-acting analogue in these papers contains an albumin-binding modification. Its results must stay separate from no-DAC listings.
What the research shows
- The human trials below measured circulating hormones and drug persistence, rather than athletic performance.
Critical interpretation
A preserved pulse is only part of the hormone profile
The overnight sampling study adds a useful qualification to the phrase preserved pulsatility. Pulse frequency and size did not significantly change, while trough GH rose. A pulsatile pattern can therefore coexist with a higher background concentration. This is evidence about the shape of an endocrine response, not proof that normal physiology has been restored or that a favourable clinical outcome follows. The paper is especially useful when a secondary account presents pulsatility as a complete safety argument. [2]
What the controlled trials can establish
The ascending-exposure trials support a causal effect of the defined long-acting analogue on measured hormone concentrations in healthy adults. Randomisation helps answer that narrow question. It does not supply an unmeasured outcome: strength, functional recovery and treatment of a deficient population would each need appropriate participants and direct endpoints. The reported persistence also belongs to the modified study molecule. It is not a generic property of every product using the CJC name. [1]
Limitations & uncertainties
- Short follow-up cannot resolve long-term safety. A catalogue name does not establish the studied formulation or an equivalent delivery profile.
Open research questions
- Which exact sequence and albumin-binding modification are documented for the material?
- Is the proposed experimental endpoint a hormone marker, or an independently measured functional outcome?
Selected papers & source records
Download bibliography1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab)
Teichman SL, Neale A, Lawrence B, et al. (2006). Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2005-1536 (opens in a new tab) · PMID 16352683
- Design & population
- Two randomized, double-blind, placebo-controlled ascending-exposure trials, lasting 28 and 49 days, in healthy adults aged 21–61.
- What the study found
- The defined long-acting analogue produced sustained increases in GH and IGF-I. Its estimated half-life was 5.8–8.1 days.
- Limits on interpretation
- Hormone concentrations and short-term tolerability were assessed. These trials did not establish improved strength, muscle performance or long-term safety.
2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (opens in a new tab)
Ionescu M, Frohman LA. (2006). Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2006-1702 (opens in a new tab) · PMID 17018654
- Design & population
- Healthy men underwent overnight blood sampling before and one week after a defined long-acting CJC-1295 intervention.
- What the study found
- GH pulses persisted, while trough and mean GH concentrations increased. Pulse frequency and magnitude were not significantly changed.
- Limits on interpretation
- An endocrine time-course experiment. Preserved pulses do not demonstrate normalisation of a disease state, improved performance or long-term safety.
Search & review scope
Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.
Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.
Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov 16352683 CJC-1295 Teichman
- site.pubmed.ncbi.nlm.nih.gov CJC-1295 no DAC modified GRF 1-29 trial
- site.pubmed.ncbi.nlm.nih.gov CJC-1295 pulsatile secretion randomized Teichman 2006
- "17018654" DOI Ionescu
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. CJC-1295 with DAC: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/cjc-1295-with-dac.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.